

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:48:44 ON 10 FEB 2007

=> file medline, biosis, uspatful, dgene, embase
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:49:20 ON 10 FEB 2007

FILE 'BIOSIS' ENTERED AT 11:49:20 ON 10 FEB 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 11:49:20 ON 10 FEB 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:49:20 ON 10 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 11:49:20 ON 10 FEB 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> s (hPEPT1)
L1 567 (HPEPT1)

=> s l1 and fusion protein
4 FILES SEARCHED...

L2 73 L1 AND FUSION PROTEIN

=> s l1 and (his-tag)
L3 5 L1 AND (HIS-TAG)

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 5 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:12027 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, UNITED STATES
Belinka, Benjamin A. JR., Kendall Park, NJ, UNITED STATES

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/Caplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/Caplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/Caplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/Caplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/Caplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/Caplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/Caplus updated with revised CAS roles
NEWS	23	JAN 22	CA/Caplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

PATENT ASSIGNEE(S): STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES
Cytogen Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007010441	A1	20070111
APPLICATION INFO.:	US 2006-356452	A1	20060217 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-79678, filed on 15 May 1998, GRANTED, Pat. No. US 7053177		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Page(s)	
LINE COUNT:	8505	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 2 OF 5 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:297361 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, UNITED STATES
Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)
Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7135457	B1	20061114
APPLICATION INFO.:	US 1998-79819		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 48 Drawing Page(s)	
LINE COUNT:	8630	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 3 OF 5 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:133579 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, UNITED STATES
Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7053177	B1	20060530
APPLICATION INFO.:	US 1998-79678		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Campell, Bruce R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	4580	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 4 OF 5 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:59889 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, United States
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, United States
Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Carter, John M., Trenton, NJ, United States

PATENT ASSIGNEE(S): Cagney, Gerard M., Seattle, WA, United States
Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6703362	B1	20040309
APPLICATION INFO.:	US 1998-79723		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	9164	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 5 USPATFULL on STN

TI Antibodies to peptides that target GIT receptors and related methods

AB The invention provides an antibody or antibody fragment specific to a domain of a GIT targeting agent, such as a polyclonal antibody, monoclonal antibody, chimeric antibody, single chain antibody, a Fab fragment or a Fab expression library. In particular, the invention provides an antibody or antibody fragment, wherein the GIT targeting agent is selected from the group consisting of ZElan033 (PAX2 15 mer), ZElan088 (HAX42-2 20 mer) or ZElan053 (P31 D-form 16 mer). Numerous methods using these GIT targeting agent specific antibodies are

disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:53408 USPATFULL
TITLE: Antibodies to peptides that target GIT receptors and related methods
INVENTOR(S): O'Mahony, Daniel Joseph, Blackrock, IRELAND
Seveso, Michela, Padua, ITALY
PATENT ASSIGNEE(S): Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699973	B1	20040302
APPLICATION INFO.:	US 1999-443780		19991119 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-109036P	19981119 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Scheiner, Laurie	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1417	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:48:44 ON 10 FEB 2007)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, EMBASE' ENTERED AT 11:49:20 ON 10 FEB 2007

L1 567 S (HPEPT1)
L2 73 S L1 AND FUSION PROTEIN
L3 5 S L1 AND (HIS-TAG)

=> s l2 and (retro-inverted peptide)
L4 0 L2 AND (RETRO-INVERTED PEPTIDE)

=> s l1 and receptor
L5 293 L1 AND RECEPTOR

=> s l5 and (retro-inverted peptide)
L6 8 L5 AND (RETRO-INVERTED PEPTIDE)

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
AN AAB03872 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also

disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length HAX42 amino acid sequence.

ACCESSION NUMBER: AAB03872 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan021 (full length HAX42).

L6 ANSWER 2 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03871 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length PAX2 amino acid sequence.

ACCESSION NUMBER: AAB03871 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia,

anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan018 (full length PAX2).

L6 ANSWER 3 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -

AN AAB03870 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI. Also included in the invention are a retro-
inverted peptide which enhances the delivery of an
active agent across the gastrointestinal tract (GIT) into the systemic,
portal or hepatic circulation. A composition comprising a retro
-inverted peptide bound to a material comprising an
active agent used to treat a mammalian disease or disorder is also
disclosed in the invention. The retro-inversion peptides target
gastrointestinal tract transport receptors to promote in vivo uptake of
active agents and/or enhance active agent delivery across the tract into
the systemic circulation. The gastrointestinal agents (containing
retro-inverted peptides) are used to facilitate the transport of active
ingredients through human or animal gastrointestinal tissue, from the
lumen to the portal, hepatic, or systemic circulation. The compositions
containing these agents can be used to treat or prevent mammalian,
especially human, diseases or disorders, especially hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and
angina pectoris. The compositions can be administered in vivo to image
selected sites or tissues, such as the gastrointestinal tract, by using
an imaging agent as the active agent. The present sequence represents a
peptide from which a retro-inversion peptide of the invention is created.
The peptide is a fragment of HAX42.

ACCESSION NUMBER: AAB03870 peptide DGENE

TITLE: Retro-inverted peptide used to
deliver active agents across the gastrointestinal tract to
treat hypertension, diabetes, osteoporosis, haemophilia,
anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan091 (HAX42
fragment).

L6 ANSWER 4 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -

AN AAB03869 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind

to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of P31.

ACCESSION NUMBER: AAB03869 peptide DGENE .
 TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
 INVENTOR: O'Mahony D J
 PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
 PATENT INFO: WO 2000031123 A2 20000602 36
 APPLICATION INFO: WO 1999-IE117 19991119
 PRIORITY INFO: US 1998-109038 19981119
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-400037 [34]
 DESCRIPTION: GIT receptor targeting peptide ZElan031 (P31 fragment).

L6 ANSWER 5 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03868 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using

an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of PAX2.

ACCESSION NUMBER: AAB03868 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan129 (PAX2 fragment).

L6 ANSWER 6 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03867 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a HAX42 14 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03867 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan146 (HAX42 fragment).

L6 ANSWER 7 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AN AAB03866 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI. Also included in the invention are a retro-
inverted peptide which enhances the delivery of an
active agent across the gastrointestinal tract (GIT) into the systemic,
portal or hepatic circulation. A composition comprising a retro
-inverted peptide bound to a material comprising an
active agent used to treat a mammalian disease or disorder is also
disclosed in the invention. The retro-inversion peptides target
gastrointestinal tract transport receptors to promote in vivo uptake of
active agents and/or enhance active agent delivery across the tract into
the systemic circulation. The gastrointestinal agents (containing
retro-inverted peptides) are used to facilitate the transport of active
ingredients through human or animal gastrointestinal tissue, from the
lumen to the portal, hepatic, or systemic circulation. The compositions
containing these agents can be used to treat or prevent mammalian,
especially human, diseases or disorders, especially hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and
angina pectoris. The compositions can be administered in vivo to image
selected sites or tissues, such as the gastrointestinal tract, by using
an imaging agent as the active agent. The present sequence represents a
retro-inversion used in the invention. The sequence is a P31 16 mer
fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03866 peptide DGENE
TITLE: Retro-inverted peptide used to
deliver active agents across the gastrointestinal tract to
treat hypertension, diabetes, osteoporosis, haemophilia,
anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan145 (P31
fragment).

L6 ANSWER 8 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AN AAB03865 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI. Also included in the invention are a retro-
inverted peptide which enhances the delivery of an
active agent across the gastrointestinal tract (GIT) into the systemic,
portal or hepatic circulation. A composition comprising a retro
-inverted peptide bound to a material comprising an
active agent used to treat a mammalian disease or disorder is also
disclosed in the invention. The retro-inversion peptides target
gastrointestinal tract transport receptors to promote in vivo uptake of
active agents and/or enhance active agent delivery across the tract into
the systemic circulation. The gastrointestinal agents (containing
retro-inverted peptides) are used to facilitate the transport of active

ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a PAX2 15 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03865 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-1E117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan144 (PAX2 fragment).

=> d his

(FILE 'HOME' ENTERED AT 11:48:44 ON 10 FEB 2007)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, EMBASE' ENTERED AT 11:49:20 ON 10 FEB 2007

L1 567 S (HPEPT1)
L2 73 S L1 AND FUSION PROTEIN
L3 5 S L1 AND (HIS-TAG)
L4 0 S L2 AND (RETRO-INVERTED PEPTIDE)
L5 293 S L1 AND RECEPTOR
L6 8 S L5 AND (RETRO-INVERTED PEPTIDE)

=> s l1 and treatment

L7 306 L1 AND TREATMENT

=> s l7 and l2

L8 70 L7 AND L2

=> s l8 and (retro-inverted peptide)

L9 0 L8 AND (RETRO-INVERTED PEPTIDE)

=> s ZElan

L10 62 ZELAN

=> s l10 and l8

L11 9 L10 AND L8

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and

derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:12027 USPATFULL
TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, UNITED STATES
Belinka, Benjamin A. JR., Kendall Park, NJ, UNITED STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Cytogen Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007010441	A1	20070111
APPLICATION INFO.:	US 2006-356452	A1	20060217 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-79678, filed on 15 May 1998, GRANTED, Pat. No. US 7053177		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Page(s)	
LINE COUNT:	8505	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system. —

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:297361 USPATFULL
TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES
 O'Mahony, Daniel J., Dublin, IRELAND
 Lambkin, Imelda J., Dublin, IRELAND
 Patterson, Catherine A., Dublin, IRELAND
 Singleton, Judith, Rocky Hill, NJ, UNITED STATES
 Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES
 Carter, John M., Trenton, NJ, UNITED STATES
 Cagney, Gerard M., Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)
 Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7135457	B1	20061114
APPLICATION INFO.:	US 1998-79819		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 48 Drawing Page(s)	
LINE COUNT:	8630	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:133579 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES
 O'Mahony, Daniel J., Dublin, IRELAND
 Lambkin, Imelda J., Dublin, IRELAND
 Patterson, Catherine A., Dublin, IRELAND
 Singleton, Judith, Rocky Hill, NJ, UNITED STATES
 Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES
 Carter, John M., Trenton, NJ, UNITED STATES
 Cagney, Gerard M., Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7053177	B1	20060530
APPLICATION INFO.:	US 1998-79678		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Campbell, Bruce R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	4580	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 4 OF 9 USPATFULL on STN

TI Conjugates of membrane translocating agents and pharmaceutically active agents

AB Membrane translation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:118304 USPATFULL

TITLE: Conjugates of membrane translocating agents and pharmaceutically active agents

INVENTOR(S): O'Mahony, Daniel, Blackrock, IRELAND
Lambkin, Imelda, Sutton, IRELAND
Pinilla, Clemencia, Cardiff, CA, UNITED STATES
Houghten, Richard, Solana Beach, CA, UNITED STATES

PATENT ASSIGNEE(S): Sarlan Ltd., Hamilton, BERMUDA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006100149	A1	20060511
APPLICATION INFO.:	US 2005-303372	A1	20051216 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-955656, filed on 30 Sep 2004, ABANDONED Continuation of Ser. No. US 2002-126845, filed on 19 Apr 2002, ABANDONED Continuation-in-part of Ser. No. US 2000-671089, filed on 27 Sep 2000, GRANTED, Pat. No. US 6780846		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
	US 2001-287786P	20010430 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2599	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 5 OF 9 USPATFULL on STN

TI Conjugates of membrane translocating agents and pharmaceutically active agents

AB Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:118487 USPATFULL
TITLE: Conjugates of membrane translocating agents and pharmaceutically active agents
INVENTOR(S): O'Mahony, Daniel, Blackrock, IRELAND
Lambkin, Imelda, Sutton, IRELAND
Pinilla, Clemencia, Cardiff, CA, UNITED STATES
Houghten, Richard, Solana Beach, CA, UNITED STATES
PATENT ASSIGNEE(S): Sarlan Ltd., Hamilton, BERMUDA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005101762	A1	20050512
APPLICATION INFO.:	US 2004-955656	A1	20040930 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-126845, filed on 19 Apr 2002, ABANDONED Continuation-in-part of Ser. No. US 2000-671089, filed on 27 Sep 2000, GRANTED, Pat. No. US 6780846		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	3597	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 9 USPATFULL on STN

TI Membrane translocating peptide drug delivery system

AB The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:211526 USPATFULL
TITLE: Membrane translocating peptide drug delivery system
INVENTOR(S): O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
PATENT ASSIGNEE(S): Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6780846	B1	20040824
APPLICATION INFO.:	US 2000-671089		20000927 (9)

NUMBER	DATE
--------	------

 PRIORITY INFORMATION: US 1999-156246P 19990927 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Carlson, Karen Cochrane
 ASSISTANT EXAMINER: Snedden, Sheridan K
 LEGAL REPRESENTATIVE: Synnestvedt & Lechner LLP
 NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 1507
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 9 USPATFULL on STN

TI Membrane translocating peptide drug delivery system
 AB The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:178962 USPATFULL
 TITLE: Membrane translocating peptide drug delivery system
 INVENTOR(S): O'Mahony, Daniel J., Blackrock, IRELAND
 Lambkin, Imelda J., Sutton, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004138132	A1	20040715
APPLICATION INFO.:	US 2004-764235	A1	20040123 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-671089, filed on 27 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1591	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
 AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of

the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:59889 USPATFULL
TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, United States
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, United States
Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Carter, John M., Trenton, NJ, United States
Cagney, Gerard M., Seattle, WA, United States
PATENT ASSIGNEE(S): Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6703362	B1	20040309
APPLICATION INFO.:	US 1998-79723		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	9164	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 9 USPATFULL on STN

TI Conjugates of membrane translocating agents and pharmaceutically active agents
AB Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:258314 USPATFULL
TITLE: Conjugates of membrane translocating agents and pharmaceutically active agents
INVENTOR(S): O'Mahony, Daniel, Blackrock, IRELAND
Lambkin, Imelda, Sutton, IRELAND
Pinilla, Clemencia, Cardiff, CA, UNITED STATES
Houghten, Richard, Solana Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181367	A1	20030925
APPLICATION INFO.:	US 2002-126845	A1	20020419 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-671089, filed on 27 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD., ATTN: ELAN, 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2144	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

Refine Search

Search Results -

Terms	Documents
7053177.pn.	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L2

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, February 10, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

DB=USPT; PLUR=YES; OP=OR

<u>L2</u>	7053177.pn.	1	<u>L2</u>
<u>L1</u>	7135457.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 7053177 B1

L2: Entry 1 of 1

File: USPT

May 30, 2006

US-PAT-NO: 7053177

DOCUMENT-IDENTIFIER: US 7053177 B1

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

DATE-ISSUED: May 30, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alvarez; Vernon L.	Morrisville	PA		US
O'Mahony; Daniel J.	Dublin			IE
Lambkin; Imelda J.	Dublin			IE
Patterson; Catherine A.	Dublin			IE
Singleton; Judith	Rocky Hill	NJ		US
Belinka, Jr.; Benjamin A.	Kendall Park	NJ		US
Carter; John M.	Trenton	NJ		US
Cagney; Gerard M.	Seattle	WA		US

US-CL-CURRENT: 530/324; 424/185.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

7053177.pn.

1

Display Format: CIT

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

First Hit	Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS					

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 7135457 B1

L1: Entry 1 of 1

File: USPT

Nov 14, 2006

US-PAT-NO: 7135457

DOCUMENT-IDENTIFIER: US 7135457 B1

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

DATE-ISSUED: November 14, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alvarez; Vernon L.	Morrisville	PA		US
O'Mahony; Daniel J.	Dublin			IE
Lambkin; Imelda J.	Dublin			IE
Patterson; Catherine A.	Dublin			IE
Singleton; Judith	Rocky Hill	NJ		US
Belinka, Jr.; Benjamin A.	Kendall Park	NJ		US
Carter; John M.	Trenton	NJ		US
Cagney; Gerard M.	Seattle	WA		US

US-CL-CURRENT: 514/12; 424/185.1, 514/15, 514/21, 530/324, 530/327, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
7135457.pn.	1

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)